JNJ 27141491

Discontinued Product

5176 has been discontinued.

View all Chemokine CC Receptors products.
说明: Potent and selective human CCR2 antagonist
化学名: 3-[(1S)-1-(3,4-Difluorophenyl)propyl]-2,3-dihydro-5-(5-isoxazolyl)-2-thioxo-1H-imidazole-4-carboxylic acid methyl ester
纯度: ≥98% (HPLC)
说明书
引用文献
评论
文献 (1)

生物活性 for JNJ 27141491

Potent, noncompetitive human CCR2 antagonist; inhibits MCP-1-induced Ca2+ mobilization in hCCR2-CHO cells (IC50 = 13 nM). Exhibits selectivity for CCR2 over CCR1, CCR3-8 and CXCR1-3. Delays onset and reduces neurological signs in an experimental autoimmune encephalomyelitis model of multiple sclerosis in hCCR2 knock-in mice. Orally active.

技术数据 for JNJ 27141491

分子量 379.38
公式 C17H15F2N3O3S
储存 Store at +4°C
纯度 ≥98% (HPLC)
CAS Number 871313-59-6
PubChem ID 11703589
InChI Key SYARXICKXVXWNA-LBPRGKRZSA-N
Smiles FC1=CC([C@H](CC)N2C(C(OC)=O)=C(C3=CC=NO3)NC2=S)=CC=C1F

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

按标靶查看相关产品

按产品操作查看相关产品

查看全部 Chemokine CC Receptor Antagonists

关键词: JNJ 27141491, JNJ 27141491 supplier, JNJ27141491, Chemokine, CC, Receptors, 5176, Tocris Bioscience

篇 JNJ 27141491 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 JNJ 27141491 的引用文献。

JNJ 27141491 的评论

目前没有该产品的评论。 Be the first to review JNJ 27141491 and earn rewards!

Have you used JNJ 27141491?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.